Dark

Check out our Level2View

CMNDF
CLEARMIND MEDICINE INC
stock OTC

Inactive

Nov 11, 2022

7.90USD+25.433%(+1.60)1,100

Pre-market

0.00USD0.000%(0.00)0

After-hours

0.00USD0.000%(0.00)0

Overview HistoricalExchangesShortsNews

Jan 31, 2022

09:30AM EST Clearmind Medicine Now Fully Eligible for Settlement through the GlobeNewswire Inc

Jan 28, 2022

09:00AM EST A renowned speaker, and bestselling author, Dr. Gabor Mat is highly sought after for his expertise on a range of topics including addiction, stress and childhood development GlobeNewswire Inc

Jan 26, 2022

09:22AM EST Clearmind Medicine Engages the Independent Trading Group as a GlobeNewswire Inc

Jan 19, 2022

09:00AM EST Clearminds Management Team Will Explain the Regulatory Process Required for Clearminds Patented MEAI Molecule to Become an FDA Approved Medicine for Treating Alcohol Use Disorder and Binge Drinking GlobeNewswire Inc

Jan 13, 2022

08:30AM EST The CPA's Panel for physicians and medical professionals addressed "New Psychedelic Substances" GlobeNewswire Inc

Jan 11, 2022

09:43AM EST Clearmind Medicine Inc. (CSE: CMND, FSE: CWY0, OTC Pink: CMNDF) (Clearmind or the "Company"), a psychedelic medicine biotech company focused on the discovery and development of novel psychedelic-derived therapeutics to solve widespread and undertreated health problems, is pleased to announce senior appointments to its management team in North America. GlobeNewswire Inc

Jan 10, 2022

08:00AM EST Clearmind Medicine Establishes Third R&D Partnership With the GlobeNewswire Inc

Nov 24, 2021

09:19AM EST Focus on the discovery and development of novel therapeutic strategies to treat obesity and its related metabolic disorders GlobeNewswire Inc

Nov 22, 2021

09:00AM EST Clearmind Medicine to Pursue Dual Listing on Nasdaq GlobeNewswire Inc

Share